E.U. Panel Backs Novartis' Mock-up Pandemic Flu Vaccine

by Medindia Content Team on  February 25, 2007 at 10:37 AM Drug News   - G J E 4
E.U. Panel Backs Novartis' Mock-up Pandemic Flu Vaccine
Europe's main medical regulator said it has adopted a positive opinion recommending the granting of a marketing authorization for Focetria, from Novartis AG (NVS) Vaccines and Diagnostics unit.

Focetria is a mock-up pandemic influenza vaccine, intended for the prevention of influenza during an officially declared pandemic situation, once the pandemic viral strain has been included. It is the second mock-up pandemic influenza vaccine to receive a positive opinion from the Committee.

Mock-up pandemic influenza vaccines are approved only for use in a declared pandemic influenza situation. The objective is to have a marketing authorization in place that can be changed quickly in the event of a pandemic to include the virus strain responsible, once it has been identified.

Source: Bio-Bio Technology

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All

More News on: